Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...

Emergency hemopoiesis may maintain blood counts and a proinflammatory environment in MDS, AML, and ICUS. Altered neutrophil subset distributions in MDS and AML show diagnostic sensitivity, with ...

Shorter-duration venetoclax may be as effective as longer-duration treatment in AML and MDS, with no significant impact on overall survival. The study included 53 patients, predominantly male, with a ...

GRAFAPEX™ (treosulfan) with fludarabine is FDA-approved for AML and MDS patients undergoing alloHSCT, showing improved overall survival compared to busulfan. Common side effects include ...

Findings showed the hazard ratio for OS compared with busulfan was 0.67 in all randomized patients. The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with ...

Researchers have tested a gene-edited stem cell transplant designed to shield healthy blood-forming cells from powerful ...

Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials We previously demonstrated that early completion of portable medical orders, known as Medical ...

The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...

The findings from Dana-Farber researcher to be presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition SAN DIEGO - Dana-Farber Cancer Institute researchers are leading ...